Bedrijfsoverzicht
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology entity that focuses on decoding biology and chemistry by integrating advanced technological innovations across the fields of biology, chemistry, automation, data science, and engineering. This strategic integration allows the company to industrialize the drug discovery process within the United States and the United Kingdom, distinguishing its operational model from traditional pharmaceutical development. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, a classification that implies a focus on early-stage innovation and high-risk, high-reward therapeutic asset creation rather than mature product commercialization. As of the latest available data, the entity holds a market capitalization of $1.73B, generates annual revenue of $74.68M, and employs approximately 600 individuals. These financial and operational figures indicate that the company maintains a significant valuation relative to its current revenue base, suggesting that the market prices the stock based on future pipeline potential rather than current profitability, a common characteristic for clinical-stage biotechs where the primary asset value lies in proprietary data platforms and intellectual property.
Financiële gezondheid
The financial statements for Recursion Pharmaceuticals, Inc. report a trailing twelve-month (TTM) revenue of $74.68M, while the net income stands at a loss of $-644,758,976, and EBITDA is reported at $-564,430,976. The substantial gap between the positive revenue figure and the deeply negative net income reveals an aggressive cost structure where operating expenses, likely driven by R&D investments and personnel costs, significantly outweigh earnings before interest and taxes. The company reports a free cash flow of $-208,521,744, which indicates that the business is currently burning cash to fund its growth initiatives and platform development rather than generating liquidity from operations. Despite this cash burn, the balance sheet shows a cash position of $743.29M against total debt of $77.97M, suggesting a conservative liquidity stance where available cash resources substantially exceed financial obligations. The debt-to-equity ratio is recorded at 6.89, a figure that, when viewed alongside the high cash reserves, reflects a leveraged balance sheet structure typical for growth companies that utilize capital to accelerate development programs. Liquidity is further supported by a current ratio of 5.50, which indicates a strong ability to meet short-term obligations with current assets, providing a significant safety margin for operational continuity. Return on Equity (ROE) is listed at -59.5% and Return on Assets (ROA) is -27.7%, metrics that mathematically demonstrate that management effectiveness, measured by shareholder returns and asset utilization, is currently negative due to the accumulation of accumulated deficits and the heavy investment in growth assets.
Waarderingsbeoordeling
Valuation metrics for Recursion Pharmaceuticals, Inc. present a complex picture due to the absence of traditional profitability measures, as the P/E Ratio (TTM) is N/A and the Forward P/E is listed at -3.85. The negative forward P/E implies that analysts or market models anticipate earnings that could turn the metric positive in the future, though the current trajectory suggests earnings are not yet profitable. The price-to-book ratio stands at 1.53, indicating that the market values the company at 53% above its book value, which suggests a premium assigned to the company's intangible assets, such as its data science platform and pipeline assets. Alternative valuation metrics like the price-to-sales ratio of 23.20 and an EV/EBITDA of -1.89 further highlight that the market is pricing the stock based on revenue generation and future potential rather than current cash flows or earnings power. Regarding price volatility, the 52-week high is $7.18 and the 52-week low is $2.80. Without a specific current price provided in the source data to calculate the exact percentage, the stock trades within a defined range where the upper limit is $7.18 and the lower limit is $2.80. The beta value is 1.01, which indicates that the stock's price volatility moves in line with the broader market, meaning it does not exhibit extreme sensitivity to general market swings compared to higher or lower beta securities.
Growth & Income
The revenue growth year-over-year is reported at an impressive 681.7%, while the earnings growth year-over-year is N/A due to the lack of prior period profitability. This disparity implies that while the company is scaling its top line rapidly, the earnings base is not yet established to support comparable percentage growth rates, a typical pattern for companies in the clinical development phase. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as indicated by the 0.0% payout ratio and N/A dividend yield. This approach signifies that the company reinvests all generated earnings and cash reserves back into research and development to fuel pipeline expansion rather than returning capital to shareholders. The overall growth and income profile is characterized by high revenue expansion coupled with negative earnings and no dividend distribution, reflecting a strategy focused entirely on capital appreciation through future commercialization of drug candidates rather than current income generation.